Objective: The prognosis of breast cancer in premenopausal women is variable and depends on the interactions between several biological factors. The androgen receptor (AR) could be one of the prognostic variables associated with survival in these patients; however, the data about this is scarce. The aim of the study was to examine the relationship between AR expression and survival outcomes in patients with estrogen receptor (ER)-positive premenopausal invasive breast carcinoma. Material and Methods: We analyzed the AR expression in premenopausal women with ER-positive invasive breast carcinomas and correlated this expression pattern with several clinical and pathological parameters, such as tumor size, lymph node status, progesterone receptor (PgR) status, and human epidermal growth factor receptor type 2 (HER-2) overexpression and evaluated the association of these parameters with survival using univariate analyses. Immunohistochemical analysis for AR, PgR, and HER-2, and semiquantitative evaluation of staining were performed. Results: AR expression was demonstrated in 61.44% of patients. There was no statistically significant association of AR with age, tumor size, lymph node status, stage, and PgR/HER-2 status (p values=0.758, 0.346, 0.604, 0.175, 0.070, 0.728, respectively). AR expression was not a prognostic factor for disease- free survival and overall survival in women with ER-positive cancer. Conclusion: AR expression was not associated with tumor size or ER/PgR/HER-2 status. Although AR expression has prognostic significance in triple-negative breast cancer, it is not a prognostic marker in hormone-positive premenopausal breast cancer.